https://www.selleckchem.com/products/cp2-so4.html
1, 95%CI 0.8-1.5; TTD HR 1.2, 95%CI 0.9-1.7). The total healthcare costs per patient during the treatment period were NT$580,523.8 for eribulin versus NT$497,223.8 for capecitabine (p0.0001), and total medication costs were NT$438,335.8 and NT$348,438.4 (p0.0001), respectively. Although eribulin showed an attenuated effect in the real-world setting in Taiwan, it may serve as an alternative for capecitabine in a heavy pretreated population. The total healthcare and medication costs were found to be higher with eribulin treatment.
Like
Comment
Share
